Search

Displaying results 1831 - 1840 of 10000 in total
  1. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

  2. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.

  4. Drug

    PPL-100

    go.drugbank.com/drugs/DB05961
    Investigational

  5. Drug

    ANZ-100

    go.drugbank.com/drugs/DB05967
    Investigational

  6. Drug

    Archexin

    go.drugbank.com/drugs/DB05971
    Investigational

    Synonyms: 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', SODIUM PHOSPHOTHIOATE
  7. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  8. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine. … INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.

    Synonyms: WT-1 analog peptide vaccine
  10. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.